DARVON-N W/ ASA
LOE Approachingaspirin; propoxyphene napsylate
NDAORALTABLET
Approved
Sep 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVON-N W/ ASA is an oral tablet combination of propoxyphene napsylate (opioid analgesic) and aspirin (NSAID) approved in 1971 for moderate pain relief. This fixed-dose combination leverages synergistic analgesic and anti-inflammatory mechanisms to manage pain across multiple etiologies.
LOE Approaching
Product is in late lifecycle stage with moderate competitive pressure (30/100), signaling a contracting team and focus on retention rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DARVON-N W/ ASA offers limited career growth and visibility given its late-lifecycle stage and zero linked job opportunities. This role is best suited for professionals seeking stability in legacy product management or those building regulatory/compliance expertise in opioid category stewardship.
Brand Manager (Lifecycle Management)Field Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.